These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686. Dhatariya K Diabetes Care; 2016 Jan; 39(1):e18. PubMed ID: 26696665 [No Abstract] [Full Text] [Related]
24. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686. Ou HY; Karnchanasorn R; Chuang LM; Chiu KC Diabetes Care; 2015 Nov; 38(11):e198. PubMed ID: 26494820 [No Abstract] [Full Text] [Related]
25. Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686. Erondu N; Desai M; Ways K; Meininger G Diabetes Care; 2016 Jan; 39(1):e19. PubMed ID: 26696666 [No Abstract] [Full Text] [Related]
26. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Erondu N; Desai M; Ways K; Meininger G Diabetes Care; 2015 Sep; 38(9):1680-6. PubMed ID: 26203064 [TBL] [Abstract][Full Text] [Related]
27. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN. Ahmed M; McKenna MJ; Crowley RK Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153 [TBL] [Abstract][Full Text] [Related]
28. Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor. Koch RA; Clark RF Am J Ther; 2018; 25(5):e590-e591. PubMed ID: 28452848 [No Abstract] [Full Text] [Related]
29. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors. Wang AY; Hou SK; Li SJ; Kao WF Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369 [No Abstract] [Full Text] [Related]
30. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases]. Menghoum N; Oriot P; Hermans MP; Mariage JL Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073 [TBL] [Abstract][Full Text] [Related]
32. Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases. Venkatesh B; Moore G; Gill D; Kelly W Crit Care Resusc; 2015 Dec; 17(4):280-2. PubMed ID: 26640065 [No Abstract] [Full Text] [Related]
33. SGLT2 Inhibitors and Ketoacidosis: Cause for Concern? Abate N; Chandalia M Metab Syndr Relat Disord; 2016 Feb; 14(1):1-2. PubMed ID: 26554527 [No Abstract] [Full Text] [Related]
35. Canagliflozin-Associated Acute Pancreatitis. Verma R Am J Ther; 2016; 23(3):e972-3. PubMed ID: 25187092 [TBL] [Abstract][Full Text] [Related]
36. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management. Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012 [TBL] [Abstract][Full Text] [Related]
37. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Blevins TC; Farooki A Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216 [TBL] [Abstract][Full Text] [Related]